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Abstract
Background: Adenovirus causes a number of diseases in human, and can cause serious infection in severely immu-
nosuppressed individuals. Despite the seriousness of adenovirus infection, there is no definitely approved anti-adenoviral
therapy. Many studies have shown that compounds derived from medicinal plants have antiviral activity. Therefore, this
study evaluated in vitro anti-adenoviral activity of ethanol extract, fractions, and main phenolic compounds of pome-
granate peel.
Methods: The ethanol extract of pomegranate peel was prepared with maceration method and fractionated by con-
secutive liquid/liquid partition. The cytotoxic and anti-adenovirus activities of the extract, fractions, and main phenolic
compounds (ellagic acid, punicalagin and gallic acid) were evaluated on Hep-2 cell line using MTT assay. Inhibitory effect
on adsorption and post-adsorption phases of the virus replication cycle was also evaluated.
Results: Pomegranate peel extract had a desirable effect against adenovirus with IC50 of 5.77 mg/mL and selectivity
index of 49.9. Among the fractions and compounds, the n-butanol fraction and gallic acid had the highest anti-adenoviral
activity with IC50 of 2.16 mg/mL and 4.67mM and selectivity indices of 122.5 and 10.5, respectively. The crude extract, n-
butanol fraction and gallic acid inhibited the virus replication in post-adsorption phase (p< 0.01).
Conclusion: Pomegranate peel extract, especially its n-butanol fraction, could serve as a new promising anti-adenovirus
agent due to high inhibitory effect against adenovirus replication. The effect of the n-butanol fraction may be related to
the synergistic effect or other compounds of this fraction. Further understanding of the bioassay guided isolation of
natural compounds of this fraction seems essential.
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Introduction
Adenoviruses (ADVs) are non-enveloped double-
stranded DNA viruses that are of over 70 types (geno-
types). Human ADVs are classified into seven species
(A–G). Generally, human ADVs are not highly patho-
genic, and are mostly associated with self-contained
respiratory infections, hemorrhagic cystitis, and gastro-
enteritis, particularly in infants and young children.1 In
addition, ocular human ADV infections are among the
leading causes of viral conjunctivitis. In immunocom-
promised patients, such as solid-organ transplant or
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hematopoietic stem cell transplant recipients, human
ADV infections leaf to high morbidity and mortality.2
In fact, human ADV is reportedly the most increased
virus in transplant recipients, especially in pediatric
units.3
No effective therapy or definitely approved drug has
yet been developed for ADV associated diseases.
Cidofovir and ribavirin are occasionally used in clinics.
Although no controlled clinical trial has yet been con-
ducted on the two drugs, they appear to exhibit activity
against ADV.4 Two problems with cidofovir are severe
central nervous system side effects and retinal toxici-
ty.4,5 Because of the lack of effective anti-adenoviral
drugs, it is necessary to develop alternative anti-
adenoviral treatments.
Attempts are being made to develop various novel
agents that may be effective against viruses, specifically
human ADV. Naturally occurring anti-viral nutrients
may be of special importance because they are widely
available and may be used as a constituent of the diet
to fight diseases, including ADV infection.
The pomegranate, botanically called Punica
granatum, belongs to the Punicaceae family. In tradi-
tional medicine, pomegranate fruit is used to relieve
hepatic failure, dry coughing, facial swelling, skin
itching, and jaundice. Pomegranate peel is also useful
for the treatment of sore throats, gastrointestinal
worms, and diarrhea.6 Metabolites in different
parts of the fruit and peel of pomegranate contain a
variety of sugars, organic acid, alkaloids, polyphenols,
tannins, flavonoids, anthocyanins, fatty acids,
vitamins, etc.6,7 Pomegranate peel is a rich source
of tannins and other phenolic compounds.8
Chidambara Murthy et al. have also reported that
pomegranate peel contains ellagic acid, ellagitannins,
and gallic acids.9
It has been observed that many plant polyphenols,
such as ellagic acid, catechins, and chlorogenic,
caffeic, and ferulic acids, act as antibacterial, antiviral,
antioxidant, anti-inflammatory, and antineoplastic
agents.10–12 In the present study, we prepared crude
ethanol extract and four fractions of pomegranate
peel, and then investigated the efficacy of these plant
materials and three main phenolic compounds of
pomegranate peel (ellagic acid, punicalagin and gallic
acid) on human ADV.
Materials and methods
Chemicals and reagents
Ethyl alcohol, n-hexane, chloroform, ethyl acetate, n-buta-
nol, and dimethyl sulfoxide (DMSO) were purchased from
CARLO ERBA Reagents (France). Butylated hydroxytol-
uene, 2,2 diphenyl-1-picrylhydrazyl, gallic acid, ellagic
acid, punicalagin, rutin, and 3-(4,5-dimethylthiazol-
2ol) 2,5-diphenyl tetrazolium bromide (MTT) were
purchased from Sigma–Aldrich (St. Louis, USA).
Folin–Ciocalteu, aluminum chloride, potassium ace-
tate, and sodium acetate were supplied from Merck
Co. (Darmstadt, Germany). Dulbecco’s Modified
Eagle’s Medium (DMEM), fetal bovine serum (FBS),
penicillin-streptomycin, and amphotericin B were pur-
chased from Gibco (USA).
Plant collection, extraction, and fractionation
P. granatum of the Malas variant was obtained from
Shahreza, Isfahan Province, Iran. The dried pomegran-
ate peels were separately pulverized to obtain uniform
powders. The peel powder (100 g) was dissolved in 80%
ethyl alcohol (400mL) and the resulting solution was
stored at room temperature for 96 h. Then, the mixture
was filtered and concentrated under nearly vacuum
pressure at 40 C in rotary evaporator. The extracts
were stored in sterile bottles under refrigerated condi-
tions until further use. The crude extract was dissolved
in ethyl alcohol/H2O and fractionated by consecutive
liquid/liquid partition with n-hexane and then with
chloroform, ethyl acetate, and n-butanol with increas-
ing polarity.13 The extract/fractions were suspended at
37 C in 10% DMSO to yield a stock solution of 10mg/
mL. This solution was filtered (MilliporeVR 0.22 mm) and
stored (at 4 C) until used. A small percentage (up to
0.2%) of DMSO present in the wells has no effect on
the results of the experiments.13
Cell and virus
Hep-2 (human laryngeal epidermal carcinoma) cells
were kindly provided by Pasteur Institute of Iran,
Tehran, Iran. The cells were grown in DMEM supple-
mented with 10% of FBS, 100 mg/mL of streptomycin,
100 UI/mL of penicillin and 0.25mg/mL amphotericin
B at 37 C with 5% CO2. The same medium containing
1.5% FBS was used for cytotoxicity and antiviral
assays. ADV (type 5) was kindly provided by the
Faculty of Health, Tehran University of Medical
Sciences, Tehran, Iran. Virus stock was prepared by
infection of 80% confluent monolayer Hep-2 cells in
75 cm2 culture flasks using DMEM with 1.5% FBS,
at 37 C in 5% CO2. Virus titer was determined by
cytopathic effect (CPE) of ADV in Hep-2 cells and
was expressed as the 50% tissue culture infective dose
(TCID50) per mL.
Cytotoxicity assay
For cytotoxicity assays, 50% cytotoxic concentrations
(CC50) of the plant materials were determined using the
MTT assay.14 Briefly, Hep-2 cells were seeded onto 96-
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well plates at a concentration of 8000 cells/well to a
final volume of 100 mL per well. After incubation at
37 C with 5% CO2 for 24 h, when the cell monolayer
was 80% confluent, the cell culture medium of cells was
aspirated and washed with phosphate-buffered saline
(PBS). Cells were incubated with 200 mL/well of various
concentrations of plant materials (in triplicate) and
incubated at 37 C with 5% CO2 for further four
days. Cell viability was examined by ability of the
cells to cleave the tetrazolium salt in the MTT assay
using succinate dehydrogenase mitochondrial enzyme,
which develops a formazan blue color product accord-
ing to a procedure that has been described earlier.14
Briefly, the supernatants were removed from the wells
and 50 mL of an MTT solution (1mg/mL in PBS) was
added to each well. The plates were incubated for 4 h at
37 C, and 100 mL of DMSO was added to the wells to
dissolve the MTT crystals. The plates were shaken on a
shaker for 15min and the absorbance was read by an
enzyme-linked immunosorbent assay reader (STATA
FAX 2100, USA) at 570 nm wavelength. Data
were calculated by the following formula and expressed
as the percentage of toxicity: toxicity (%)¼ (100 (At/
As) 100)%, where At and As refer to the absorbance
of the test substance and the solvent control, respec-
tively.13,14 The CC50 was defined by nonlinear
regression.
Antiviral assay
Antiviral activity of the plant materials was evaluated
by testing their inhibitory activity using the MTT assay
according to a procedure described previously.12
Briefly, 100 mL (100 TCID50) of virus suspension was
added to at least 80% of confluent HEp-2 cell mono-
layer in a 96-well plate and incubated at 37 C for
about 2 h to allow virus adsorption. Then, serial two-
fold dilutions that had been prepared from non-toxic
dose of the plant materials were added and the result-
ing solution was tested in triplicate. To prepare positive
control, cells were infected with the same concentration
of virus but without addition of plant materials. To
prepare negative or cell control, only DMEM and
1.5% FBS were added to the cells. The plates were
incubated at 37 C in a humidified CO2 atmosphere
for four days.
Cell viability was also determined using previously
described MTT assay.14 Data were calculated and
expressed as the percentage of inhibition using the fol-
lowing formula: antiviral activity (%) ¼ (Atv  Acv)/
(Acd  Acv) 100%, where Atv, Acv, and Acd represent
the absorbance of the test compounds on virus-infected
cells, the absorbance of the virus control and the
absorbance of the cell control, respectively. The proce-
dure was carried out in triplicate. The 50% inhibitory
concentration (IC50) was determined from a curve
relating inhibition to the concentration of the
plant materials. The CC50/IC50 was calculated to deter-
mine selectivity index (SI), an index of antiviral
activity.
Mode of antiviral activity
To assess the mechanism of antiviral activity, the time-
of-addition effect of the plant materials with better
anti-adenoviral effects (crude extract, n-butanol frac-
tion and gallic acid) was evaluated according to a
previously described procedure with minor modifica-
tions.15 Infected cell cultures were treated with one
time IC90 of the plant materials (crude extract
11.8 mg/mL, n-butanol fraction 4.1 mg/mL and gallic
acid 12.4 mM) at three different times: (1) after adsorp-
tion and until the end of the experiment (post-adsorp-
tion); (2) during and after the adsorption (throughout);
and (3) during the adsorption (adsorption; Figure 1).
To conduct these experiments, 80% confluent cells
were infected with 100 TCID50 (100 mL/well) of the
virus in the presence or absence of plant materials
and further incubated at 37 C for 2 h so that only
the adsorption step of the viral particles to the cells
(adsorption) was performed. Then, the supernatant
was replaced with the medium and 1.5% FBS with or
without the plant materials, and then incubated for
four days at 37 C with 5% CO2. Cell viability and
the percentage of virus inhibition were also evaluated
compared with the control using the previously
described MTT assay. The procedure was carried out
in triplicate.
Statistical analysis
All experiments were carried out in triplicate. The IC50
and CC50 were calculated using dose-response analyses
and related models with probit procedure in the SPSS.
Significance level (p) was considered <0.05.
Figure 1. Scheme of addition of plant materials in the adsorp-
tion and post-adsorption phases of the virus. Open and black
arrows indicate the absence and presence of plant materials,
respectively.
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Results
Cytotoxicity and antiviral assay
Cytotoxic activities of plant extracts, fractions, and
components were evaluated using Hep-2 cell line. The
CC50 of pomegranate peel crude extract on Hep-2 cells
was 288.2 mg/mL. The ethyl acetate fraction showed the
highest cytotoxic activity with a CC50 of 32.4 mg/mL.
Other fractions including n-butanol, chloroform, and
n-hexane had a CC50 of 264.7, 151.4, and 125.9 mg/
mL, respectively. Among the compounds, ellagic acid
exhibited the highest cytotoxicity on the Hep-2
cells with a CC50 of 7.05 mm/mL (Table 1). The analysis
demonstrated that the extract concentration was signif-
icantly associated with the cell death (p< 0.05,
Figure 2).
The antiviral activity showed that pomegranate peel
extract had a desirable effect against ADV with an IC50
Figure 2. Cytotoxicity and anti-adenoviral activity of crude extract, n-butanol fraction, and gallic acid of pomegranate peel. Eighty
percent confluent Hep-2 cells without virus infection or infected with virus were exposed to different concentrations of crude
extract, n-butanol fraction, and gallic acid for 96 h. Cell viability was measured by the MTT test. Values are expressed as mean
(standard error of measurement) of three experiments.
Table 1. Cell cytotoxicity, anti-adenoviral activity, and selectivity index of the crude extract, fractions, and main
phenolic compounds of pomegranate peel.
Sample CC50 (CI 95%) IC50 (CI 95%) SI
Crude extract (mg/mL) 288.2 (257.4–322.6) 5.77 (5.12–6.51) 49.95
n-Hexane fraction (mg/mL) 125.95 (90–164.5) >125.95 <1
Chloroform fraction (mg/mL) 151.4 (128.5–178) 30.47 (3.27–58.1) 4.96
Ethyl acetate fraction (mg/mL) 32.4 (28.19–37.26) 5.41 (4.79–6.12) 5.98
n-Butanol fraction (mg/mL) 264.7 (234.9–298.4) 2.16 (1.94–2.41) 122.5
Gallic acid (mM) 49.34 (44.6–52.02) 4.67 (4.29–5.08) 10.5
Ellagic acid (mM) 7.048 (5.84–8.5) >7.048 <1
Punicalagin (mM) 13.58 (1255–14.69) 4.48 (3.79–5.31) 3.03
CC50: 50% cytotoxicity concentration; IC50: 50% inhibitory concentration; CI 95%: confidence interval 95 ℅, SI: selectivity index.
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of 5.77 (CI 95%: 5.12–6.51) mg/mL, and SI of 49.9. Out
of the fractions and compounds, the n-butanol fraction
and gallic acid had the highest anti-adenoviral activity
with an IC50 of 2.16 (CI 95%: 1.94–2.41) mg/mL and
4.67 (CI 95%: 4.3–5.1) mM and a SI of 122.5 and 10.5,
respectively (Table 1). Our results showed that the
higher the extract concentration, the more pronounced
the CPE inhibition (Figure 2, p< 0.05).
Characterization of antiviral activity
Various experiments were carried out with one time
IC90 of the plant materials with better anti-adenoviral
effects to assess the mechanism of their antiviral action
in the adsorption and post-adsorption phases of ADV
replication (Figure 3). Our results showed that crude
extract, n-butanol fraction and gallic acid inhibited
ADV replication in the post-adsorption phase
(p< 0.01). There was no significant difference in the
percentage of post-adsorption virus inhibition when
these plant materials were present during all the exper-
imental time (throughout phase; Figure 3).
Discussion
In this study the inhibitory effect of crude extract, frac-
tions, and main phenolic compounds of pomegranate
peel on ADV in Hep-2 cell lines were investigated. Our
results approved antiviral effect of pomegranate peel
extract with IC50 of 5.77 mg/mL and SIs of 49.9.
Among the fractions and compounds, the n-butanol
fraction and gallic acid had the highest anti-
adenoviral activity with an IC50 of 2.16mg/mL and
4.67 mM and a SI of 122.5 and 10.5, respectively.
As the IC50 of the herbal extract against infectious
diseases is less than 100 mg/mL,16 this extract and its
n-butanol fraction should have strong activity
against ADV.
Fifteen percent of pomegranate peel contains phe-
nolic compounds including 8% ellagic acid, 3% puni-
calagin, and 0.8% gallic acid.17 According to previous
studies, ellagic acid and gallic acid have anti-mutation,
antiviral and antioxidant activities.18 In addition, puni-
calagin has been reported to exhibit a wide range of
biological activities including antiviral effects on
human immunodeficiency virus,19 influenza virus20
and herpes simplex virus.21
Because the anti-adenoviral effect of the pomegran-
ate peel n-butanol fraction with a very high SI can be
attributed to its main compounds including gallic acid,
ellagic acid or punicalagin, the anti-adenoviral effects
of these compounds were studied. The results of our
study show that these compounds have a lower anti-
adenoviral effect than the ethanolic fraction of pome-
granate peel. Accordingly, it seems that the effect
observed for the n-butanol fraction is related to the
synergistic effects of the compounds present in this
fraction, or other compounds. This argument needs
to be further investigated.
Based on the results of this study, we suggest that in
future studies, the amount of phenolic compounds in
pomegranate peel fractions be evaluated using accurate
methods such as high-performance liquid chromatog-
raphy. Anti-adenoviral activity of punicalagin, com-
bined with gallic acid, can also be evaluated to
investigate its synergistic effect. We hope this study
and supplemental research help to discover and pro-
duce effective compounds for the treatment of adeno-
viral diesis.
Various experiments were carried out with one time
IC90 of the plant materials with better anti-adenoviral
effects to assess the mechanism of their antiviral action
in the adsorption and post-adsorption phases of ADV
replication. Our results showed that crude extract,
n-butanol fraction and gallic acid inhibited ADV rep-
lication in the post-adsorption phase. Based on our
findings, the extract, n-butanol fraction, and gallic
acid did not prevent the entry of ADV into Hep-2
cell but acted after penetration of the virus into the
cell. This finding is in agreement with the results of
other studies that have demonstrated medicinal plant
extract reduces the viral titer when they are added after
the adsorption phase.15,22
Conclusion
Based on our results, pomegranate peel extract, espe-
cially its n-butanol fraction, could serve as a new prom-
ising anti-ADV agent due to its high inhibitory effect
Figure 3. The effect of crude extract, n-butanol fraction, and
gallic acid of pomegranate peel on the adsorption and post-
adsorption of adenovirus. Data, expressed as meanstandard
error of measurement, show the percentage of virus inhibition
compared with untreated control. One time 90% inhibitory
concentration was used in this experiment. Statistical analysis
was done by one-way analysis of variance followed by Tukey’s
test. **p< 0.001 for adsorption vs. post-adsorption and
throughout.
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against ADV replication. The effect of the n-butanol
fraction may be related to the synergistic effect or other
compounds of this fraction. Further understanding of
the action mechanism and the bioassay guided isolation
of natural components of this fraction seems essential.
More characterization of this extract probably leads to
development of potential anti-adenoviral agents.
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